Rameen Beroukhim, M.D., Ph.D., Dana-Farber Cancer Institute (image) Dana-Farber Cancer Institute Share Print E-Mail Caption Rameen Beroukhim, M.D., Ph.D., and his colleagues at Dana-Farber Cancer Institute and Broad Institute scientists report that large-scale genomic sequencing has revealed two DNA mutations that appear to drive about 15 percent of meningiomas. Experimental drugs that inhibit these mutant gene pathways are in clinical trials and have shown promising activity, suggesting that targeted therapies already in development or use may work against these specific meningiomas. Credit Sam Ogden Usage Restrictions None Share Print E-Mail Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.